Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 11, 2015

Primary Completion Date

February 11, 2016

Study Completion Date

February 11, 2017

Conditions
Adult Form of Celiac Disease
Interventions
OTHER

Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.

After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER

NCT02389062 - Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients | Biotech Hunter | Biotech Hunter